Enzyme-Based Aesthetics Arrive in North America in Landmark Deal

RICHMOND HILL, ON – April 13, 2026 – A strategic new partnership is set to introduce a novel class of aesthetic treatments to the United States and Canada, potentially shifting the focus of cosmetic enhancement from simple volume to biological skin quality. Phiusion Labs Inc., a new venture led by a seasoned industry veteran, today announced it will be the exclusive North American distributor for PBSerum®, a portfolio of advanced enzymatic solutions developed by the Spanish biotechnology firm Proteos Biotech S.L.

The agreement positions Phiusion Labs to roll out this innovative, science-driven product line to physicians across a market hungry for the next evolution in non-invasive procedures. The move signals a growing demand for treatments that work with the body's own biology, offering a new frontier in the pursuit of healthier, more youthful-looking skin.

A New Biological Frontier in Skin Quality

PBSerum® represents a significant departure from conventional aesthetic modalities. While dermal fillers focus on volume replacement and energy-based devices stimulate tissue through mechanical or thermal means, PBSerum® employs a "biologically inspired approach" centered on patented recombinant enzyme technology. These enzymes are designed to interact directly with the extracellular matrix—the complex network of proteins and molecules that provides structural and biochemical support to skin cells.

Developed by Proteos Biotech, the technology uses genetic recombination to produce bacterial-origin enzymes that mimic those found in the human body. This process yields highly purified, stable, and effective enzymes with low immunogenicity, enhancing safety. To preserve 100% of their activity without preservatives, the enzymes undergo lyophilization, or freeze-drying, a sophisticated process that also eliminates the need for cold storage.

The PBSerum® portfolio includes a range of proprietary enzymes, each with a specific target:

• Collagenase: Works to break down disorganized or aged collagen fibers, promoting the synthesis of new, healthy collagen. This is particularly effective for improving the appearance of scars and fibrosis.
• Lipase: Targets and breaks down fat cells, activating lipid metabolism to reduce localized fat deposits without causing tissue destruction.
• Lyase: Reduces water retention and inflammation by targeting polysaccharides, increasing tissue permeability and improving fluid balance.
• Keratinase: Promotes cell regeneration and improves the skin's permeability, enhancing the absorption and efficacy of active ingredients.

Clinical data has already shown promising results. One study on a PBSerum® formulation demonstrated an 11% improvement in skin elasticity after 28 days, with 96% subject satisfaction and no adverse events. With patient satisfaction rates for various enzyme treatments ranging from 86% to over 94%, the technology has proven its efficacy and safety in markets outside North America.

Strategic Play in a Multi-Billion Dollar Market

The entry of PBSerum® into North America comes at a time of explosive growth in the non-invasive aesthetics sector. Valued at nearly USD $9 billion in 2024, the market is projected to grow at a compound annual growth rate (CAGR) of over 7%. Injectables are the dominant force, accounting for more than half of all revenue. PBSerum® is poised to compete directly in this lucrative segment while offering a distinct value proposition.

"The United States and Canada represent a key strategic market for us," said Juan Ramón Muñoz Montaño, CEO of Proteos Biotech S.L. "We are pleased to partner with Phiusion Labs Inc., whose experience in physician education and market development makes them an ideal partner to support the introduction of PBSerum®."

At the helm of Phiusion Labs is Founder and CEO Ario Khoshbin, an entrepreneur with a formidable track record. Khoshbin previously founded Prollenium Medical Technologies, which he grew from a small startup into a global aesthetics powerhouse, notably becoming the only manufacturer of hyaluronic acid dermal fillers in North America and securing a coveted FDA approval for its products.

Khoshbin's new venture, Phiusion Labs, aims to commercialize next-generation technologies in regenerative medicine and skin health. This new partnership is a cornerstone of that mission.

"Having worked in the medical aesthetics field for over two decades... it is clear that practitioners are increasingly seeking solutions that go beyond traditional approaches," stated Khoshbin. "PBSerum® brings a unique and biologically inspired perspective to the market, and we are excited to support its introduction across North America."

Beyond Fillers: Expanding the Practitioner's Toolkit

For aesthetic practitioners, the arrival of PBSerum® promises to expand their toolkit beyond existing options. The product line is intended to complement, not necessarily replace, current modalities. By incorporating enzymatic activity into treatment protocols, physicians gain the ability to address aspects of skin texture, firmness, and overall quality that may not be fully resolved with traditional techniques.

This offers a more holistic and potentially more natural-looking outcome for patients. Instead of just filling a line or wrinkle, the treatment aims to improve the underlying health and structure of the skin itself. Phiusion Labs has committed to a robust rollout strategy focused on structured physician education, hands-on training programs, and clinical integration support to ensure practitioners can confidently and effectively incorporate this new technology into their practices.

Navigating the Path to Market

Bringing any new medical product to the North American market is a complex undertaking, with stringent regulatory oversight from the FDA in the United States and Health Canada. The press release notes that product availability and indications are subject to local approvals. However, the path for PBSerum® may be smoother than for many newcomers.

Crucially, certain formulations within the PBSerum® line are already FDA-approved for indications such as treating localized fat, cellulite, fibrosis, and scarring. This existing regulatory clearance provides a significant advantage, de-risking the market entry for those specific products and setting a strong precedent for the broader portfolio. Proteos Biotech’s adherence to international certifications for manufacturing sterile pharmaceuticals and medical devices further bolsters its position for navigating the remaining regulatory hurdles.

As Phiusion Labs begins its educational and commercialization efforts, the North American aesthetics industry will be watching closely. In a competitive landscape dominated by giants like AbbVie, Galderma, and Merz, the success of PBSerum® will depend on its ability to demonstrate a clear clinical advantage and effectively communicate its unique, biology-first approach to both physicians and the growing number of patients seeking advanced, science-backed skin treatments.